From: Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Characteristic | Total | Advanced | Non-advanced | P-value |
---|---|---|---|---|
Number of patients | 108 | 51 | 57 | |
Age, years | 66.7 ± 7.9 | 66.4 ± 8.6 | 68.2 ± 7.2 | 0.236 |
Male | 86 (79.6) | 39 (76.5) | 47 (82.5) | 0.441 |
Smoking status | 0.027 | |||
Never smoker | 25 (23.1) | 16 (31.4) | 9 (15.8) | |
Former smoker | 79 (73.1) | 35 (68.6) | 44 (77.2) | |
Current smoker | 4 (3.7) | 0 (0.0) | 4 (7.0) | |
Body mass index, kg/m2 | 23.3 ± 3.2 | 22.7 ± 3.4 | 24.2 ± 2.7 | 0.018 |
Time since diagnosis, months | 39.7 ± 32.0 | 41.2 ± 35.3 | 38.9 ± 29.1 | 0.709 |
Comorbidities | ||||
Diabetes mellitus | 22 (20.4) | 9 (17.6) | 13 (22.8) | 0.506 |
Cardiovascular disease | 11 (10.2) | 4 (7.8) | 7 (12.3) | 0.447 |
Cerebrovascular disease | 4 (3.7) | 3 (5.9) | 1 (1.8) | 0.642 |
Chronic liver disease | 3 (2.8) | 2 (3.9) | 1 (1.8) | 0.601 |
Pulmonary function test | ||||
FVC, % predicted | 56.2 ± 15.1 | 46.8 ± 9.5 | 65.3 ± 13.5 | < 0.001 |
DLco, % predicted | 35.7 ± 12.6 | 27.1 ± 9.8 | 43.6 ± 9.4 | < 0.001 |
TLC, % predicted | 58.0 ± 12.2 | 50.8 ± 7.6 | 65.0 ± 11.5 | < 0.001 |
6MWT | ||||
Distance, m | 341.2 ± 122.5 | 275.0 ± 107.4 | 411.9 ± 96.4 | < 0.001 |
Lowest SaO2, % | 84.2 ± 5.3 | 82.8 ± 4.8 | 87.4 ± 4.8 | < 0.001 |
SPAP, mmHga | 36.4 ± 1.1 | 38.8 ± 13.0 | 34.2 ± 9.2 | 0.039 |
Previous treatment | ||||
Pirfenidone | 20 (18.5) | 10 (19.3) | 10 (17.5) | 0.783 |
Prednisolone | 17 (15.7) | 13 (25.5) | 4 (7.0) | 0.008 |
Immunosuppressants | 11 (10.2) | 9 (17.6) | 2 (3.5) | 0.015 |
N-Acetylcysteine | 5 (4.6) | 0 (0.0) | 5 (8.8) | 0.059 |
None | 66 (60.6) | 26 (51.0) | 40 (70.2) | 0.041 |